Clinical Trials on Acinar Cell Adenocarcinoma of the Pancreas

Total 2028 results

Mohammed Najeeb Al Hallak
National Cancer Institute (NCI)

Completed

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic Cancer

United States
John DeWitt
American Society for Gastrointestinal Endoscopy; Pinnacle Biologics Inc.

Completed

Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Terminated

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IIB Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Case Comprehensive Cancer Center

Completed

Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage I-III Pancreatic Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Yale University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage I Pancreatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Mayo Clinic

Completed

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Roswell Park Cancer Institute
Bayer

Completed

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Unspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Edward Kim
National Cancer Institute (NCI); Takeda

Completed

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Translational Oncology Research International

Completed

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

Lung Metastases | Liver Metastases | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Centre Leon Berard
Merck Sharp & Dohme LLC; Debiopharm International SA

Completed

Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA)

Adenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

France
Samyang Biopharmaceuticals Corporation

Unknown

Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the Pancreas

Korea, Republic of
Kyowa Hakko Kirin Pharma, Inc.
Teva Pharma

Completed

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Adenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Pancreatic Acinar Cell Carcinoma

United States
James Cleary, MD, PhD
Lustgarten Foundation; Arcus Biosciences, Inc.

Recruiting

Switch Maintenance in Pancreatic

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Squamous Cell Carcinoma of Pancreas | Adenosquamous Carcinoma of the Pancreas

United States
University of Michigan Rogel Cancer Center

Completed

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas

United States
National Cancer Institute, Naples

Recruiting

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Adenocarcinoma of the Pancreas

Italy, Spain
West Virginia University

Recruiting

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas

United States
Baptist Health South Florida
AstraZeneca

Terminated

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Adenocarcinoma of the Pancreas

United States
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
National Taiwan University Hospital

Recruiting

Most Total Pancreatectomies for Ductal Adenocarcinoma Can Be Replaced by Whipple Over the Splenic Artery: A Before and After Study

Ductal Adenocarcinoma of the Pancreas

Taiwan
Eastern Regional Medical Center

Terminated

Safety & Efficacy Study of Gemcitabine...With High Dose IV Vit. C (HDIVC)

Metastatic Adenocarcinoma of the Pancreas

United States
University Hospital, Lille
Ministry of Health, France

Recruiting

Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula (TPIAT-01)

Adenocarcinoma of the Pancreas | Ampullary Adenocarcinoma | Adenocarcinoma of the Duodenum

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Stand Up To Cancer; Aduro Biotech, Inc.; American Association... and other collaborators

Completed

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Previously Treated Metastatic Adenocarcinoma of the Pancreas

United States
Accelerated Community Oncology Research Network
Amgen

Terminated

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal Stomach

United States
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Sky Foundation

Active, not recruiting

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma | Borderline Resectable Adenocarcinoma of the Head of the Pancrease

United States, Canada
Abramson Cancer Center at Penn Medicine

Completed

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Adenocarcinoma of the Pancreas

United States
The Cooper Health System

Terminated

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
Joseph J. Cullen
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaborators

Active, not recruiting

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Adenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic

United States
The Cooper Health System

Unknown

A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the Pancreas

United States
AIO-Studien-gGmbH
Celgene Corporation; ClinAssess GmbH

Completed

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (NEOLAP)

Ductal Adenocarcinoma of the Pancreas

Germany
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
HistoSonics, Inc.

Not yet recruiting

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy (GANNON)

Pancreatic Cancer | Pancreas Cancer | Adenocarcinoma of the Pancreas | Tumor of Pancreas

Spain
Pathway Genomics

Terminated

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

Lung Neoplasms | Lung Cancer | Adenocarcinoma of the Lung | Cancer of the Lung | Small Cell Carcinoma of the Lung | Non Small Cell Carcinoma of the Lung

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
David A. Clump, MD, PhD

Completed

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas

United States
Minneamrita Therapeutics LLC

Recruiting

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Korea, Republic of
Jules Bordet Institute
Innate Pharma

Withdrawn

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (ARTEMIS-Eso)

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus

Belgium
Foundation for Liver Research

Withdrawn

Pancreatic Enzyme Suppletion in Pancreatic Cancer (EPC)

Adenocarcinoma of the Pancreas | Normal Pancreatic Exocrine Function

Netherlands
Laboratorio Elea Phoenix S.A.

Completed

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Squamous Cell Carcinoma of the Cervix | Adenocarcinoma of the Cervix

Argentina

Clinical Trials on Acinar Cell Adenocarcinoma of the Pancreas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations